NXTN yields 67.80% · ABBV yields 3.06%● Live data
📍 NXTN pulled ahead of the other in Year 1
Combined, NXTN + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of NXTN + ABBV for your $10,000?
Next10, Inc. engages in the development, manufacture, and sale of security systems for the cargo transportation industry primarily in the United States and Canada. The company offers 'Bulldog Online Security Systems' (BOSS), which is designed to prevent cargo theft from cargo containers, tractor-trailers, cargo vans, tanker trucks, storage year containers, and other cargo transportation and storage equipment. Its products alert onsite security personnel in the event of theft or tampering; alert the driver in the event someone attempts to access the cargo; and monitors multiple roll-up and sliding doors, prevents unauthorized entry and intrusion, and alert the driver through a mobile receiver a thief attempt to enter, move, or remove items from the delivery vehicle. The company's BOSS line of products primarily include The Yard BOSS, The Road BOSS, The Tanker BOSS, Bulldogs BOSS Tracker, and Mini BOSS System. It offers its products to retail, pharmaceutical, high technology, and government markets. The company was formerly known as Bulldog Technologies, Inc. and changed its name to Next10, Inc. on March 25, 2011. Next10, Inc. was incorporated in 1998 and is based in Placentia, California.
Full NXTN Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.